Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin ...
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ...
On the final night of its tour-opening four-concert stand at the Kia Forum in Los Angeles, the reunited Rush continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results